IMMUNO-COV™ – The Test for Antibodies that Block SARS-CoV-2 Infection Read More

November 5-7, 2021

International Oncolytic Virus Conference (IOVC)

Dr. Kah Whye Peng was presented with the Golden Virus Award for her outstanding contribution to the field of virotherapy.

Visit event site

Dr. Stephen J. Russell, Vyriad, CEO; Dr. Kah-Whye Peng, Vyriad, CTO; Dr. Luke Russell, Vyriad, Director of Alliance Management and Vino Raj, Vyriad, Medical Director, attended the Annual IOVC in Sedona, AZ.  Dr. Kah Whye Peng was presented with the Golden Virus Award for her outstanding contribution to the field of virotherapy.

The following presentations all addressed Vyriad technologies, including both clinical and preclinical programs:

Shruthi Naik, Ph.D., Vyriad
Safety and Efficacy of Neoadjuvant Intravesical Oncolytic MV-NIS in Patients with Urothelial Carcinoma

Miguel A Muñoz Alía, Ph.D., Vyriad
Measles Virus, Stealthed and Retargeted
Read presentation

Rianna Vandergaast, Ph.D., Imanis Life Sciences
Using the IMMUNO-COV Clinical Assay for SARS-CoV-2-Neutralizing Antibodies to Track Titer Declines in Individuals Following Vaccination
View presentation

Joselle Cook, M.D., Mayo Clinic
Clinical Activity of Systemic VSV-IFNβ-NIS Oncolytic Virotherapy in Patients with Hematologic Malignancies
Read presentation

Evanthia Galanis, M.D., Mayo Clinic
First in Human Testing of Measles Virus Infected Mesenchymal Stem Cells

Haifei Jiang, Ph.D., Mayo Clinic
Herpes viral Combination Therapy for Targeting Both Cancer Cells and Cancer Associated Stromal Cells
View presentation

Richard Vile, Ph.D., Mayo Clinic
Combining CAR-T Cell Therapy with Oncolytic Viruses
View presentation

Karol Budzik, Ph.D., Mayo Clinic
Development and Characterization of a Foamy Virus-Based Oncolytic Replicating Retroviral Vector
Read presentation

Autumn Schulze, Ph.D., Mayo Clinic
Synthetic Infectious RNA-Based Oncolytic Immunotherapy
View presentation

Media Inquiries

For inquiries, please contact mediarelations@vyriad.com